Browsing by Author "Tatic, Svetislav B. (6701763955)"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance; [Änderungen im Expressionsmuster von apoptotischen Molekülen (Galectin-3, Bcl-2, Bax, Survivin) im Rahmen der Progression der Malignität von Schilddrüsentumoren und deren klinische Bedeutung](2015) ;Selemetjev, Sonja A. (24463032600) ;Savin, Svetlana B. (35568292500) ;Paunovic, Ivan R. (55990696700) ;Tatic, Svetislav B. (6701763955)Cvejic, Dubravka (7003808274)Background: Papillary carcinoma of the thyroid (PTC) is generally a slow growing tumor with favorable prognosis, while anaplastic thyroid carcinoma (ATC) is highly aggressive malignancy. Genetic defects in apoptotic pathways may contribute to differences in their biological behavior. Methods: In this study, we analyzed immunohistochemically the expression of apoptosis-related molecules: galectin-3, Bcl-2, survivin (antiapoptotic), and Bax (pro-apoptotic), in archival tissue sections of PTC (n = 69) and ATC (n = 30) and correlated the results with clinicopathological parameters of these tumors. Results: Galectin-3 and Bcl-2 showed a similar trend of down-regulation from high levels of both in PTC to low levels in ATC (p < 0.05). Bax was expressed at high levels in both type of thyroid carcinoma. Expression of survivin increased from PTC to ATC (p < 0.05), which may, at least in part, further facilitate the ability of malignant thyroid cell of ATC to escape programmed cell death despite high Bax expression. Only survivin, but not galectin-3, Bcl-2, or Bax, correlated significantly with lymph node metastasis presence and advanced stages of malignancy. Conclusions: In conclusion, this study documented down-regulation of galectin-3 and Bcl-2 (antiapoptotic molecules) and stepwise increase of survivin (inhibitor of apoptosis), during thyroid tumor progression from PTC to ATC. Correlation of high survivin expression with aggressive behavior implies its role in progression of thyroid tumor malignancy and suggests that survivin could be a useful tool in the prediction of aggressiveness of a subset of papillary carcinomas and a possible target for molecular therapy for ATC patients. © 2014, Springer-Verlag Wien. - Some of the metrics are blocked by yourconsent settings
Publication Galectin-3 expression in papillary thyroid carcinoma: Relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size(2005) ;Cvejic, Dubravka S. (7003808274) ;Savin, Svetlana B. (35568292500) ;Petrovic, Ivana M. (57197968536) ;Paunovic, Ivan R. (55990696700) ;Tatic, Svetislav B. (6701763955)Havelka, Marija J. (7004544911)Background. Galectin-3 has been recently recognized as a promising presurgical marker of thyroid malignancy. Methods. Galectin-3 expression was examined immunohistochemically in 202 specimens of papillary thyroid carcinoma (PTC) in relation to histomorphologic subtypes and clinicopathologic data. Results. The sensitivity of galectin-3 immunostaining versus conventional histology was 98% (100 of 102) for classical PTC, 85.2% (46 of 54) for follicular variant, and 50% (23 of 46) for follicular/solid variant of PTC. All cases (n = 36) involving lymph node metastases and 42 of 45 cases with extrathyroid invasion expressed galectin-3. However, among the galectin-3-positive cases (n = 169), 133 were without lymph node metastases, and 127 were without extrathyroid invasion. Galectin-3 expression was not related to the size of intrathyroid PTC. Conclusions. Galectin-3 immunohistochemical expression itself is not an indicator of local metastatic spread or extrathyroid invasion of PTC, thus being irrelevant clinically from this aspect. Galectin-3 is an excellent marker for classical PTC but must be used with caution in diagnosing unconventional variants of PTC because of the possibility of false-negative results. © 2005 Wiley Periodicals, Inc.
